Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × isatuximab × Plasma cell × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 52 Recurrence 5 Neoplasms 5 Neoplasms, Plasma Cell 4 Renal Insufficiency 3 Paraproteinemias 3 Neoplasms by Histologic Type 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Hematologic Diseases 2 Blood Protein Disorders 2 Smoldering Multiple Myeloma 1 Purpura 1 Neoplasm, Residual 1 Nausea 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoproliferative Disorders 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Immunoproliferative Disorders 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1 Hepatomegaly 1 Hematologic Neoplasms 1 Gastrointestinal Hemorrhage 1 Diarrhea 1

Interventions

Lenalidomide 5 Dexamethasone 4 fludarabine phosphate 2 daratumumab 2 Whole-Body Irradiation 2 Cyclophosphamide 2 Calcium Dobesilate 2 talquetamab 1 selinexor 1 ixazomib 1 isatuximab 1 fludarabine 1 Transplantation, Autologous 1 Sirolimus 1 Rituximab 1 Mycophenolic Acid 1 Melphalan 1 Bortezomib 1 Blood Specimen Collection 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡